129 related articles for article (PubMed ID: 23052314)
1. Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening.
Depuydt CE; Benoy IH; Beert JF; Criel AM; Bogers JJ; Arbyn M
J Clin Microbiol; 2012 Dec; 50(12):4073-7. PubMed ID: 23052314
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
[TBL] [Abstract][Full Text] [Related]
3. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
6. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
[TBL] [Abstract][Full Text] [Related]
7. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
[TBL] [Abstract][Full Text] [Related]
11. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay.
Benoy I; Xu L; Vanden Broeck D; Poljak M; Oštrbenk Valenčak A; Arbyn M; Bogers J
J Clin Virol; 2019 Nov; 120():57-62. PubMed ID: 31569008
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Oštrbenk A; Xu L; Arbyn M; Poljak M
J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
[TBL] [Abstract][Full Text] [Related]
13. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
[TBL] [Abstract][Full Text] [Related]
14. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test.
Shen Y; Gong J; He Y; Cheng G; Okunieff P; Li X
J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290
[TBL] [Abstract][Full Text] [Related]
15. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.
Heideman DA; Hesselink AT; van Kemenade FJ; Iftner T; Berkhof J; Topal F; Agard D; Meijer CJ; Snijders PJ
J Clin Microbiol; 2013 Nov; 51(11):3653-7. PubMed ID: 23985912
[TBL] [Abstract][Full Text] [Related]
16. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.
Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Doutre S; Michelow P; Kelly H; Didelot MN; Chikandiwa A; Sawadogo B; Delany-Moretlwe S; Meda N; Costes V; Mayaud P; Segondy M
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):162-8. PubMed ID: 25394189
[TBL] [Abstract][Full Text] [Related]
17. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears.
Salimović-Bešić I; Tomić-Čiča A; Smailji A; Hukić M
J Virol Methods; 2013 Dec; 194(1-2):222-8. PubMed ID: 24036071
[TBL] [Abstract][Full Text] [Related]
19. A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China.
Lin CQ; Chen F; Liu B; Zhang YZ; Cui XL; Li AM; Zhang WH; Chen W; Chang I; Sivasubramaniam P; Zhu J; Qiao YL
J Virol Methods; 2014 Jun; 202():73-8. PubMed ID: 24642241
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection.
Kwon MJ; Roh KH; Park H; Woo HY
J Clin Virol; 2014 Apr; 59(4):246-9. PubMed ID: 24568964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
